Indeed, the link between ODS1/2 and an increased risk of tumor progression was maintained when excluding patients with specific characteristics potentially impacting PFS, such as those who received targeted agents (cetuximab or bevacizumab) in association with chemotherapy in the first-line setting, or those who underwent surgical excision of metastatic lesions. Here, ME2 is linked to neoplasm.